Eiger Biopharmaceuticals Inc (EIGR) Receives Consensus Rating of “Buy” from Brokerages
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has been assigned an average recommendation of “Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $32.67.
Several analysts have recently weighed in on the stock. Ladenburg Thalmann Financial Services assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday. They set a “buy” rating and a $32.00 price target for the company. ValuEngine raised shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Oppenheimer set a $34.00 price target on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, December 7th. Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research note on Wednesday, October 25th. Finally, Roth Capital assumed coverage on shares of Eiger Biopharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $35.00 price target for the company.
Shares of Eiger Biopharmaceuticals (NASDAQ EIGR) opened at $14.50 on Friday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.78 and a current ratio of 5.78. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $14.84. The firm has a market cap of $150.91, a P/E ratio of -2.74 and a beta of 2.55.
A number of large investors have recently modified their holdings of EIGR. Sphera Funds Management LTD. raised its stake in Eiger Biopharmaceuticals by 35.0% in the third quarter. Sphera Funds Management LTD. now owns 520,269 shares of the biotechnology company’s stock worth $5,723,000 after buying an additional 134,968 shares in the last quarter. P.A.W. Capital Corp bought a new position in Eiger Biopharmaceuticals in the third quarter worth approximately $880,000. Goldman Sachs Group Inc. bought a new position in Eiger Biopharmaceuticals in the second quarter worth approximately $272,000. Susquehanna International Group LLP bought a new position in Eiger Biopharmaceuticals in the second quarter worth approximately $114,000. Finally, OxFORD Asset Management LLP bought a new position in Eiger Biopharmaceuticals in the third quarter worth approximately $147,000. 47.06% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/05/eiger-biopharmaceuticals-inc-eigr-receives-consensus-rating-of-buy-from-brokerages.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.